

PJP PowerShares Dynamic Pharmaceuticals Portfolio



As of Dec. 31, 2014

Fund Description

The PowerShares Dynamic Pharmaceuticals Portfolio is based on the Dynamic Pharmaceutical IntellidexSM Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Intellidex. The Intellidex thoroughly evaluates companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex is comprised of common stocks of 30 US pharmaceuticals companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund's return may not match the return of the Underlying Index. Concentrated industry investments involve greater risks than more diversified investments.


Fund Data

Dynamic Pharmaceuticals Portfolio	PJP
Intraday NAV (IIV)	PJP1V
CUSIP	73935X799
Listing Exchange	NYSE Arca
Number of Securities	27
30-Day SEC Yield	0.46%
30-Day SEC Unsubsidized Yield	0.46%
Total Expense Ratio	0.58%

Underlying Index Data

Dynamic Pharmaceuticals Intellidex	DZR
Index Provider	NYSE Arca

Growth of \$10,000



Data beginning Fund inception and ending Dec. 31, 2014. Fund performance shown at NAV.

Fund Performance & Index History (%)

	1 year	3 year	5 year	10 year	Fund Inception
Underlying Index					
Dynamic Pharmaceutical Intellidex Index	28.86	36.33	31.48	–	19.01
Benchmark Index					
S&P Pharmaceuticals Index	22.25	23.89	18.05	10.08	10.18
Fund					
NAV	28.10	35.47	30.63	–	18.26
After Tax Held	26.62	34.78	30.18	–	17.98
After Tax Sold	16.03	28.45	25.51	–	15.55
Market Price	28.25	35.41	30.64	–	18.27

Returns less than one year are cumulative. Performance data quoted represents past performance. Past performance is not a guarantee of future results; current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and Shares, when redeemed, may be worth more or less than their original cost. See invescopowershares.com to find the most recent month-end performance numbers. After Tax Held represents total return after taxes on distributions and assumes Shares have not been sold. After Tax Sold represents total return after taxes on distributions and the sale of Fund Shares. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Fund performance reflects fee waivers, absent which, performance data quoted would have been lower.

5-Year Index Statistics

	Alpha	Beta	Correlation	Sharpe Ratio	Volatility (%)
Dynamic Pharmaceutical Intellidex Index	–	–	–	2.30	13.64
S&P Pharmaceuticals Index	12.93	0.94	0.79	1.58	11.40

Alpha, beta and correlation are that of the underlying index.

A Smart Beta Portfolio

Fund Inception: June 23, 2005

Index returns do not represent Fund returns. An investor cannot invest directly in an index.

Neither the underlying Index nor the benchmark indexes charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown; nor do any of

the indexes lend securities, and no revenues from securities lending were added to the performance shown. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in the Fund.

The S&P Composite 1500[®] Pharmaceuticals (S&P Pharmaceuticals) Index consists of all pharmaceuticals

stocks included in the S&P Composite 1500 Index.

Shares are not FDIC insured, may lose value and have no bank guarantee.

Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 50,000 Shares.

As of Dec. 31, 2014

Top Fund Holdings (%)		Annual Index Performance (%)		
Name	Weight		Dynamic Pharmaceutical Intellidex Index	S&P Pharmaceuticals Index
Eli Lilly	5.11	2006	10.95	15.59
Bristol-Myers Squibb	5.08	2007	1.25	4.09
Pfizer	5.05	2008	-9.81	-17.92
Celgene	4.97	2009	17.77	18.93
Johnson & Johnson	4.88	2010	28.62	2.00
Amgen	4.87	2011	20.55	18.17
Merck	4.79	2012	25.62	13.94
Gilead Sciences	4.74	2013	56.53	36.53
Salix Pharmaceuticals	3.57	2014	28.86	22.25
Novavax	3.54			
Biogen Idec	3.52			
Perrigo	3.33			
DepoMed	3.32			
Prestige Brands	3.31			
Medicines	3.29			
Hospira	3.28			
Abbott Laboratories	3.23			
Baxter International	3.22			
Auxilium Pharmaceuticals	3.17			
Allergan	3.17			
Impax Laboratories	3.16			
Ligand Pharmaceuticals	3.15			
Mylan	3.07			
Actavis	3.03			
Akorn	2.88			
Lannett	2.78			
BioDelivery Sciences International	2.50			

Fund Details		Fund Market-Cap Allocations (%)	
P/B Ratio	4.52	Large-Cap Blend	4.88
P/E Ratio	27.18	Large-Cap Growth	39.04
Return on Equity	14.57%	Large-Cap Value	18.18
Weighted Market Cap (\$MM)	70,803	Mid-Cap Blend	3.32
		Mid-Cap Growth	6.47
		Mid-Cap Value	-
		Small-Cap Blend	3.38
		Small-Cap Growth	24.74
		Small-Cap Value	-

Fund Subindustry Allocations (%)	
Pharmaceuticals	68.76
Biotechnology	24.79
Health Care Equipment	6.45

Please see the website for complete holdings information. Holdings are subject to change.

Leading the Intelligent ETF Revolution®

About risk

The Fund is considered non-diversified and may be subject to greater risks than a diversified fund.

Equity risk states that the value of equity securities, including common stocks, may fall due to both changes in general economic and political conditions that impact the market as a whole, as well as factors that directly relate to a specific company or industry.

Investments focused in a particular industry or sector, such as the pharmaceuticals service industry are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

Securities lending involves a risk of loss because the borrower may fail to return the securities in a timely manner or at all. If a Fund is unable to recover the securities loaned, it may sell the collateral and purchase a replacement security in the market. Lending securities entails a risk of loss to the Funds if and to the extent that the market value of the loaned securities increases and the collateral is not increased accordingly.

Investing in securities of small and medium-sized companies may involve greater risk than is customarily associated with investing in large companies.

The **Intraday NAV** is a symbol representing estimated fair value based on the most recent intraday price of underlying assets. **Volatility** is the annualized standard deviation of index returns. **Sharpe Ratio** is a risk-adjusted measure calculated using standard deviation and excess return to

determine reward per unit of risk. A higher Sharpe Ratio indicates better risk-adjusted performance.

Correlation indicates the degree to which two investments have historically moved in the same direction and magnitude. **Alpha** is a measure of performance on a risk-adjusted basis. **Weighted Harmonic Average Stock Price-to-Earnings Ratio (P/E Ratio)** is the share price divided by earnings per share. It is measured on a 12-month trailing basis. **Weighted Harmonic Average Stock Price-to-Book-Value Ratio (P/B Ratio)** is the ratio of a stock's market price to a company's net asset value.

Weighted Harmonic Average is a method of calculating an average value that lessens the impact of large outliers and increases the impact of small ones. **Weighted Average Return on Equity** is net income divided by net worth. **Weighted Market Capitalization** is the sum of each underlying securities' market value. The **30-Day SEC Yield** is based on a 30-day period and is computed by dividing the net investment income per share earned during the period by the maximum offering price per share on the last day of the period. The **30-Day SEC Unsubsidized Yield** reflects the 30-day yield if the investment adviser were not waiving all or part of its fee or reimbursing the fund for part of its expenses. Total return would have also been lower in the absence of these temporary reimbursements or waivers.

Beta is a measure of risk representing how a security is expected to respond to general market movements. **Smart Beta** represents an alternative and selection index based methodology that seeks to outperform a benchmark or reduce portfolio risk, or both. Smart beta funds may underperform cap-weighted benchmarks and increase portfolio risk.

Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.

The Global Industry Classification Standard was developed by and is the exclusive property and a service mark of MSCI, Inc. and Standard & Poor's.

The Intellidex™ Indexes are trademarks of NYSE Euronext or its affiliates and are licensed for use by Invesco PowerShares Capital Management LLC in connection with the PowerShares Intellidex investment products. The products are not sponsored or endorsed by NYSE Arca, and NYSE Arca makes no warranty or representation as to the accuracy and/or completeness of the Indexes or results to be obtained by any person from use of the Indexes or the trading of the products.

Invesco Distributors, Inc. is the distributor of the PowerShares Exchange-Traded Fund Trust.

PowerShares® is a registered trademark of Invesco PowerShares Capital Management LLC. Invesco PowerShares Capital Management LLC and Invesco Distributors, Inc. are indirect, wholly owned subsidiaries of Invesco Ltd.

Before investing, investors should carefully read the prospectus/summary prospectus and carefully consider the investment objectives, risks, charges and expenses. For this and more complete information about the Fund call 800 983 0903 or visit invescopowershares.com for the prospectus/summary prospectus.

Note: Not all products available through all firms or in all jurisdictions.